Drug · Small Molecule

Irbesartan

CI-DRUG-00000311Explore in graph →NCIt C29130 CHEMBL1513 CIViC Approved

Regulatory

Approvals (3)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

openfdaRegulatory3 approval records · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
US FDA	—	Efficacy supplement 2002-09-17 (see label)	approved	Sep 17, 2002	openfda
US FDA	—	Efficacy supplement 2001-05-26 (see label)	approved	May 26, 2001	openfda
US FDA	—	Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria.	approved	Sep 30, 1997	openfda

Data updated 3 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	—	0	0	0	0	3	US	Sep 30, 1997	—

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Data updated 14 hours agoSource updated unknown

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FOS Overexpression1
Irbesartan	Colon Adenocarcinoma

Clinical trials

Trials with this intervention (0)

Data not yet available

No registered study lists this drug as an intervention yet.

Molecule

Record

Kind: Small Molecule
Mechanism: Type-1 angiotensin II receptor antagonist
Targets: 1 gene
UNII: J0E2756Z7N
Aliases: Aprovel, Avapro, AVAPRO, BMS-186295, Ifirmasta, Irbesartan, Irbesartan bms, Irbesartan component of avalide, Irbesartan component of coaprovel, Irbesartan component of ibersartan/hydrochlorothiazide ibersartan, Irbesartan component of ibersartan/hydrochlorothiazide teva ibersartan, Irbesartan component of ibersartan/hydrochlorothiazide zentiva ibersartan, Irbesartan component of ifirmacombi, Irbesartan teva, Irbesartan zentiva, Irbesartan zentiva (previously irbesartan winthrop), Karvea, NSC-758696, Sabervel, Sarbevel, SR 47436

Data updated 18 hours agoSource updated unknown

Identifiers

Codes (0)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

Data not yet available

No cross-reference code recorded yet beyond the record identifiers above.

Regulatory status is jurisdiction-specific and time-bound. Nothing on this page is a treatment recommendation.